Monday, October 26, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
News articleNasdaq· February 26, 2026

Stocks Mostly Lower as Nvidia Earnings Fail to Impress

View original at nasdaq.com
Stocks Mostly Lower as Nvidia Earnings Fail to Impress The S&P 500 Index ($SPX) (SPY) today is down -0.35%, the Dow Jones Industrial Average ($DOWI) (DIA) is up +0.29%, and the Nasdaq 100 Index ($IUXX) (QQQ) is down -0.75%…
Opening lines of the source · Nasdaq · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Q4 revenue of $11.20 billion, above consensus of $11.17 billion

    80% confidence
  • Q4 revenue of $596.4 million, stronger than consensus of $578.3 million

    80% confidence
  • Beating expectations is disgusting and one of the shames of capitalism

    80% confidence
  • Pure Storage outlook points to decelerating growth

    80% confidence
  • Full-year revenue forecast of $300 million to $410 million, weaker than consensus of $422.1 million

    80% confidence
  • Full-year free cash flow forecast of $1.90 billion, below consensus of $1.94 billion

    80% confidence
  • Q1 outlook above expectations

    80% confidence
  • Q4 net revenue of $4.49 billion, weaker than consensus of $4.51 billion

    80% confidence
  • Creative and positive ideas were exchanged and discussions have been positive so far and will continue

    80% confidence
  • Full-year revenue forecast of $2.63 billion to $2.67 billion, better than consensus of $2.60 billion

    80% confidence
  • Q4 revenue of $8.15 billion, above consensus of $8.12 billion

    80% confidence
  • Q4 sales of $721.6 million, well above consensus of $639 million

    80% confidence
  • Threatened to raise global tariff rate to 15%

    80% confidence
  • Gave Iran a March 1-6 deadline for an agreement over nuclear activities and threatened military strikes if it fails to comply

    80% confidence
  • Considering a limited military strike on Iran to ramp up pressure on the country to strike a deal over its nuclear program

    80% confidence
  • Q1 revenue forecast of $678 million, below consensus of $688.8 million

    80% confidence
  • Q1 revenue forecast of $11.03 billion to $11.08 billion, stronger than consensus of $10.99 billion

    80% confidence
  • Q4 data center revenue was $62.3 billion, stronger than consensus of $60.36 billion

    80% confidence
  • Iranian officials are again pursuing their sinister nuclear ambitions

    80% confidence
  • Q4 adjusted EPS of $6.42, well below consensus of $7.03

    80% confidence
  • Will continue to exclude data center revenue in China from forecasts due to concerns about Chinese government approval

    80% confidence
  • Excluding Magnificent Seven megacap technology stocks, Q4 earnings expected to increase by 4.6%

    80% confidence
  • S&P earnings growth expected to climb by 8.4% in Q4, marking the tenth consecutive quarter of year-over-year growth

    80% confidence
  • Q2 adjusted EPS of 83 cents, below consensus of 89 cents

    80% confidence
  • Cut full-year adjusted EPS to $3.93-$4.01 from previous forecast of $3.95-$4.11, weaker than consensus of $4.05

    80% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biotech Catalyst Window: ESMO Data, the Ivonescimab PDUFA and Small-Cap Delistings
Mid-October to November 2026 is a dense catalyst period for clinical-stage biotech. Positive late-stage readouts (ALOFT-IPF, TELIGAN, MIUDELLA, the duvakitug extension) and the ESMO 2026 presentations lead up to the FDA's 14 November PDUFA date for the ivonescimab BLA. At the opposite end of the market, Spago Nanomedical is moving to delist from Nasdaq First North, which shows how hard it is for micro-cap developers to fund themselves. Value is concentrating in companies with late-stage data and near-term regulatory outcomes.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,500 source documents archived
Query this data → isubstrate.com